Literature DB >> 14751506

The bioreductive agent RH1 and gamma-irradiation both cause G2/M cell cycle phase arrest and polyploidy in a p53-mutated human breast cancer cell line.

Joo-Young Kim1, Chul-Hwan Kim, Ian J Stratford, Adam V Patterson, Jolyon H Hendry.   

Abstract

PURPOSE: RH1 is a newly developed bioreductive agent, and its bioactivation is mediated by the enzyme DT-diaphorase (DTD). We have shown previously that RH1 is highly cytotoxic against cells expressing high DTD, using the p53-mutated MDA231 human breast cancer cell line transfected with the DTD gene (D7 cells). We now report that both RH1 and gamma-irradiation cause D7 cells to arrest in the G2/M cell cycle phase and undergo polyploidy. The latter is a way of p53-mutated cells responding to DNA-damaging agents. Only a small proportion of the polyploid cells are clonogenic, hence polyploidy may contribute to the reproductive failure of the cells after RH1 and irradiation. Thus, we investigated the effect of RH1 and gamma-irradiation on the formation of polyploid cells and a sub-G1 population (as a measure of apoptosis) in relation to the G2/M cell cycle block. METHODS AND MATERIALS: MDA231 D7 cells were treated using a range of RH1 doses. The cells were irradiated using 2 Gy or 5 Gy gamma-rays either as a single dose or in combination with RH1. An IC(90) dose (dose to kill 90% of the cells) of RH1 was administered for 3 h followed by irradiation after a further 24 h. Subsequent changes in cell cycle and polyploidy (DNA content in excess of that of G2/M cells) were examined.
RESULTS: Treatment of D7 cells with the RH1 resulted in 60-70% of cells arrested in the G2/M phase of the cell cycle by 24 h, which decreased to control levels by 48 h. Irradiation with 2 Gy and 5 Gy caused a similar G2/M block at 12-24 h, which was followed by a sharp decline at 24-48 h. In contrast, the same dose of radiation combined with RH1 held the cells in the G2/M phase up to 48 h, and this pattern reached pretreatment levels at 72-96 h. Most control cells were found to contain a small number of spontaneously arising polyploid cells. The development of polyploid cells was evident from 12 h after all treatments and showed a significant increase at 48 h and subsequently. As opposed to this, apoptosis measured by the sub-G1 cell population in DNA analyses showed a tendency to increase according to the elapsed time for each group of treatments. Single treatments with RH1 caused a significant increase in the apoptotic population between 48 and 120 h. The first significant increase in apoptosis was observed at 48 h for 5 Gy, 2 Gy + RH1, and 5 Gy + RH1 treatments, and showed a tendency to increase further at later times, but the 2 Gy dose gave an earlier apoptotic peak at 24 h, which decreased to 96 h. The addition of RH1 to the irradiation did not increase the formation of polyploid cells or apoptosis compared with radiation alone (2 Gy vs. RH1 + 2 Gy or 5 Gy vs. RH1 + 5 Gy). The higher dose of irradiation (5 Gy vs. 2 Gy) resulted in a significantly higher proportion of polyploid cells (but not of apoptotic cells) when used alone or in combination (5 Gy + RH1 vs. 2 Gy + RH1).
CONCLUSIONS: Both RH1 and gamma-irradiation, individually and in combination, showed a significant G2/M block in MDA231 D7 breast cancer cells. The formation of polyploid cells was dependent more on the radiation dose rather than on the pretreatment with RH1. The polyploid cell population was observed after the G2/M cell cycle phase arrest, and it preceded the late increase of the apoptotic cell population. The role of polyploidy in cell reproductive failure in the total cell population is not known, but it appears to contribute to cytotoxicity in cells released from the G2/M cell cycle phase block.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751506     DOI: 10.1016/j.ijrobp.2003.09.040

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Effect of radiation treatment on newly established human breast cancer cell lines MACL-1 and MGSO-3.

Authors:  Caryne Margotto Bertollo; Cristiane Rodrigues Correa; Dawidson Assis Gomes; Elaine Maria Souza-Fagundes; Alfredo Miranda Goes
Journal:  Tumour Biol       Date:  2010-04-27

2.  The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase.

Authors:  Moon-Taek Park; Min-Jeong Song; Eun-Taex Oh; Hyemi Lee; Bo-Hwa Choi; Seong-Yun Jeong; Eun-Kyung Choi; Heon Joo Park
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

3.  The 2,6-disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells.

Authors:  Tze-Chen Hsieh; Frank Traganos; Zbigniew Darzynkiewicz; Joseph M Wu
Journal:  Int J Oncol       Date:  2007-12       Impact factor: 5.650

4.  MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma.

Authors:  Pasqualino de Antonellis; Chiara Medaglia; Emilio Cusanelli; Immacolata Andolfo; Lucia Liguori; Gennaro De Vita; Marianeve Carotenuto; Annamaria Bello; Fabio Formiggini; Aldo Galeone; Giuseppe De Rosa; Antonella Virgilio; Immacolata Scognamiglio; Manuela Sciro; Giuseppe Basso; Johannes H Schulte; Giuseppe Cinalli; Achille Iolascon; Massimo Zollo
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

5.  Distinct activation mechanisms trigger the trypanocidal activity of DNA damaging prodrugs.

Authors:  Emma Louise Meredith; Ambika Kumar; Aya Konno; Joanna Szular; Sam Alsford; Karin Seifert; David Horn; Shane R Wilkinson
Journal:  Mol Microbiol       Date:  2017-08-31       Impact factor: 3.501

6.  Reversine, a substituted purine, exerts an inhibitive effect on human renal carcinoma cells via induction of cell apoptosis and polyploidy.

Authors:  Li Cheng; Hao Wang; Kecun Guo; Zicheng Wang; Zhongyuan Zhang; Cheng Shen; Liang Chen; Jian Lin
Journal:  Onco Targets Ther       Date:  2018-02-26       Impact factor: 4.147

7.  Synthesis and antitumor evaluation of novel bis-triaziquone derivatives.

Authors:  Cheng Hua Huang; Hsien-Shou Kuo; Jia-Wen Liu; Yuh-Ling Lin
Journal:  Molecules       Date:  2009-06-29       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.